-
1
-
-
84859012401
-
-
National Cancer Institute, Surveillance Epidemiology and End Results, Availble from: URL
-
National Cancer Institute, Surveillance Epidemiology and End Results. Pancreas. SEER Stat Fact Sheets. Availble from: URL: http://seer.cancer.gov/statfacts/html/pancreas.html
-
Pancreas. SEER Stat Fact Sheets
-
-
-
2
-
-
76049128595
-
Estimates of cancer incidence and mortality in Europe in 2008
-
Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-781
-
(2010)
Eur J Cancer
, vol.46
, pp. 765-781
-
-
Ferlay, J.1
Parkin, D.M.2
Steliarova-Foucher, E.3
-
3
-
-
0242491491
-
Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine
-
Ziske C, Schlie C, Gorschlüter M, Glasmacher A, Mey U, Strehl J, Sauerbruch T, Schmidt-Wolf IG. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer 2003; 89: 1413-1417
-
(2003)
Br J Cancer
, vol.89
, pp. 1413-1417
-
-
Ziske, C.1
Schlie, C.2
Gorschlüter, M.3
Glasmacher, A.4
Mey, U.5
Strehl, J.6
Sauerbruch, T.7
Schmidt-Wolf, I.G.8
-
4
-
-
8244254377
-
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
-
Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413
-
(1997)
J Clin Oncol
, vol.15
, pp. 2403-2413
-
-
Burris, H.A.1
Moore, M.J.2
Andersen, J.3
Green, M.R.4
Rothenberg, M.L.5
Modiano, M.R.6
Cripps, M.C.7
Portenoy, R.K.8
Storniolo, A.M.9
Tarassoff, P.10
Nelson, R.11
Dorr, F.A.12
Stephens, C.D.13
von Hoff, D.D.14
-
5
-
-
73949135518
-
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer
-
Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, Falk S, Crellin A, Adab F, Thompson J, Leonard P, Ostrowski J, Eatock M, Scheithauer W, Herrmann R, Neoptolemos JP. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009; 27: 5513-5518
-
(2009)
J Clin Oncol
, vol.27
, pp. 5513-5518
-
-
Cunningham, D.1
Chau, I.2
Stocken, D.D.3
Valle, J.W.4
Smith, D.5
Steward, W.6
Harper, P.G.7
Dunn, J.8
Tudur-Smith, C.9
West, J.10
Falk, S.11
Crellin, A.12
Adab, F.13
Thompson, J.14
Leonard, P.15
Ostrowski, J.16
Eatock, M.17
Scheithauer, W.18
Herrmann, R.19
Neoptolemos, J.P.20
more..
-
6
-
-
34249933404
-
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group
-
Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966
-
(2007)
J Clin Oncol
, vol.25
, pp. 1960-1966
-
-
Moore, M.J.1
Goldstein, D.2
Hamm, J.3
Figer, A.4
Hecht, J.R.5
Gallinger, S.6
Au, H.J.7
Murawa, P.8
Walde, D.9
Wolff, R.A.10
Campos, D.11
Lim, R.12
Ding, K.13
Clark, G.14
Voskoglou-Nomikos, T.15
Ptasynski, M.16
Parulekar, W.17
-
7
-
-
0036682041
-
Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297
-
Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20: 3270-3275
-
(2002)
J Clin Oncol
, vol.20
, pp. 3270-3275
-
-
Berlin, J.D.1
Catalano, P.2
Thomas, J.P.3
Kugler, J.W.4
Haller, D.G.5
Benson, A.B.6
-
8
-
-
34250180939
-
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: A randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
-
Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Köhne CH, Mingrone W, Stemmer SM, Tàmas K, Kornek GV, Koeberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007; 25: 2212-2217
-
(2007)
J Clin Oncol
, vol.25
, pp. 2212-2217
-
-
Herrmann, R.1
Bodoky, G.2
Ruhstaller, T.3
Glimelius, B.4
Bajetta, E.5
Schüller, J.6
Saletti, P.7
Bauer, J.8
Figer, A.9
Pestalozzi, B.10
Köhne, C.H.11
Mingrone, W.12
Stemmer, S.M.13
Tàmas, K.14
Kornek, G.V.15
Koeberle, D.16
Cina, S.17
Bernhard, J.18
Dietrich, D.19
Scheithauer, W.20
more..
-
9
-
-
33748445708
-
Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer
-
Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006; 24: 3946-3952
-
(2006)
J Clin Oncol
, vol.24
, pp. 3946-3952
-
-
Heinemann, V.1
Quietzsch, D.2
Gieseler, F.3
Gonnermann, M.4
Schönekäs, H.5
Rost, A.6
Neuhaus, H.7
Haag, C.8
Clemens, M.9
Heinrich, B.10
Vehling-Kaiser, U.11
Fuchs, M.12
Fleckenstein, D.13
Gesierich, W.14
Uthgenannt, D.15
Einsele, H.16
Holstege, A.17
Hinke, A.18
Schalhorn, A.19
Wilkowski, R.20
more..
-
10
-
-
20644464360
-
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial
-
Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïeb J, Faroux R, Lepere C, de Gramont A. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23: 3509-3516
-
(2005)
J Clin Oncol
, vol.23
, pp. 3509-3516
-
-
Louvet, C.1
Labianca, R.2
Hammel, P.3
Lledo, G.4
Zampino, M.G.5
André, T.6
Zaniboni, A.7
Ducreux, M.8
Aitini, E.9
Taïeb, J.10
Faroux, R.11
Lepere, C.12
de Gramont, A.13
-
11
-
-
4644327989
-
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate
-
Rocha Lima CM, Green MR, Rotche R, Miller WH, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G, Miller LL. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004; 22: 3776-3783
-
(2004)
J Clin Oncol
, vol.22
, pp. 3776-3783
-
-
Rocha, L.C.M.1
Green, M.R.2
Rotche, R.3
Miller, W.H.4
Jeffrey, G.M.5
Cisar, L.A.6
Morganti, A.7
Orlando, N.8
Gruia, G.9
Miller, L.L.10
-
12
-
-
33749071359
-
Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer
-
Abou-Alfa GK, Letourneau R, Harker G, Modiano M, Hurwitz H, Tchekmedyian NS, Feit K, Ackerman J, De Jager RL, Eckhardt SG, O'Reilly EM. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 2006; 24: 4441-4447
-
(2006)
J Clin Oncol
, vol.24
, pp. 4441-4447
-
-
Abou-Alfa, G.K.1
Letourneau, R.2
Harker, G.3
Modiano, M.4
Hurwitz, H.5
Tchekmedyian, N.S.6
Feit, K.7
Ackerman, J.8
de Jager, R.L.9
Eckhardt, S.G.10
O'Reilly, E.M.11
-
13
-
-
27144530079
-
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer
-
Oettle H, Richards D, Ramanathan RK, van Laethem JL, Peeters M, Fuchs M, Zimmermann A, John W, Von Hoff D, Arning M, Kindler HL. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005; 16: 1639-1645
-
(2005)
Ann Oncol
, vol.16
, pp. 1639-1645
-
-
Oettle, H.1
Richards, D.2
Ramanathan, R.K.3
van Laethem, J.L.4
Peeters, M.5
Fuchs, M.6
Zimmermann, A.7
John, W.8
von Hoff, D.9
Arning, M.10
Kindler, H.L.11
-
14
-
-
0037100983
-
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer
-
Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002; 87: 161-167
-
(2002)
Br J Cancer
, vol.87
, pp. 161-167
-
-
Bramhall, S.R.1
Schulz, J.2
Nemunaitis, J.3
Brown, P.D.4
Baillet, M.5
Buckels, J.A.6
-
15
-
-
2342645506
-
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer
-
Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Verslype C, Neumann H, Safran H, Humblet Y, Perez Ruixo J, Ma Y, Von Hoff D. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22: 1430-1438
-
(2004)
J Clin Oncol
, vol.22
, pp. 1430-1438
-
-
van Cutsem, E.1
van de Velde, H.2
Karasek, P.3
Oettle, H.4
Vervenne, W.L.5
Szawlowski, A.6
Schoffski, P.7
Post, S.8
Verslype, C.9
Neumann, H.10
Safran, H.11
Humblet, Y.12
Perez, R.J.13
Ma, Y.14
von Hoff, D.15
-
16
-
-
65549150854
-
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer
-
Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, Verslype C, Scheithauer W, Shang A, Cosaert J, Moore MJ. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009; 27: 2231-2237
-
(2009)
J Clin Oncol
, vol.27
, pp. 2231-2237
-
-
van Cutsem, E.1
Vervenne, W.L.2
Bennouna, J.3
Humblet, Y.4
Gill, S.5
van Laethem, J.L.6
Verslype, C.7
Scheithauer, W.8
Shang, A.9
Cosaert, J.10
Moore, M.J.11
-
17
-
-
0037083621
-
Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: A prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale
-
Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, Cigolari S, Testa A, Maiello E, Lopez M. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002; 94: 902-910
-
(2002)
Cancer
, vol.94
, pp. 902-910
-
-
Colucci, G.1
Giuliani, F.2
Gebbia, V.3
Biglietto, M.4
Rabitti, P.5
Uomo, G.6
Cigolari, S.7
Testa, A.8
Maiello, E.9
Lopez, M.10
-
18
-
-
33748297529
-
A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer
-
Stathopoulos GP, Syrigos K, Aravantinos G, Polyzos A, Papakotoulas P, Fountzilas G, Potamianou A, Ziras N, Boukovinas J, Varthalitis J, Androulakis N, Kotsakis A, Samonis G, Georgoulias V. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer 2006; 95: 587-592
-
(2006)
Br J Cancer
, vol.95
, pp. 587-592
-
-
Stathopoulos, G.P.1
Syrigos, K.2
Aravantinos, G.3
Polyzos, A.4
Papakotoulas, P.5
Fountzilas, G.6
Potamianou, A.7
Ziras, N.8
Boukovinas, J.9
Varthalitis, J.10
Androulakis, N.11
Kotsakis, A.12
Samonis, G.13
Georgoulias, V.14
-
19
-
-
41949106225
-
Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer
-
author reply 1179
-
Boeck S, Heinemann V. Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer. J Clin Oncol 2008; 26: 1178-119; author reply 1179
-
(2008)
J Clin Oncol
, vol.26
, pp. 1178-1179
-
-
Boeck, S.1
Heinemann, V.2
-
20
-
-
33344475959
-
Oxaliplatin/folinic acid/5-fluorouracil [24h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003)
-
Oettle H, Pelzer U, Stieler J, Hilbig A, Roll L, Schwaner I, Adler M, Detken S, Dörken B, Riess H. Oxaliplatin/folinic acid/5-fluorouracil [24h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003). J Clin Oncol 2005; 23: 4031
-
(2005)
J Clin Oncol
, vol.23
, pp. 4031
-
-
Oettle, H.1
Pelzer, U.2
Stieler, J.3
Hilbig, A.4
Roll, L.5
Schwaner, I.6
Adler, M.7
Detken, S.8
Dörken, B.9
Riess, H.10
-
21
-
-
0018578870
-
Colorectal carcinoma antigens detected by hybridoma antibodies
-
Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979; 5: 957-971
-
(1979)
Somatic Cell Genet
, vol.5
, pp. 957-971
-
-
Koprowski, H.1
Steplewski, Z.2
Mitchell, K.3
Herlyn, M.4
Herlyn, D.5
Fuhrer, P.6
-
22
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors
-
European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
Wanders, J.4
Kaplan, R.S.5
Rubinstein, L.6
Verweij, J.7
van Glabbeke, M.8
van Oosterom, A.T.9
Christian, M.C.10
Gwyther, S.G.11
-
23
-
-
84859020036
-
-
SNFGE, Available from: URL
-
SNFGE. Thésaurus de cancérologie digestive. Available from: URL: http://www.thesaurus-cancerologie.org/
-
Thésaurus De Cancérologie Digestive
-
-
-
24
-
-
42949098425
-
Optimal second line treatment options for gemcitabine refractory advanced pancreatic cancer patients. Can we establish standard of care with available data?
-
Kang SP, Saif MW. Optimal second line treatment options for gemcitabine refractory advanced pancreatic cancer patients. Can we establish standard of care with available data? JOP 2008; 9: 83-90
-
(2008)
JOP
, vol.9
, pp. 83-90
-
-
Kang, S.P.1
Saif, M.W.2
-
25
-
-
48949087810
-
A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study
-
Pelzer U, Kubica K, Stieler J, Schwaner I, Heil G, Görner M, Mölle M, Hilbig A, Dörken B, Riess H, Oettle H. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 2008; 26: A4058
-
(2008)
J Clin Oncol
, vol.26
-
-
Pelzer, U.1
Kubica, K.2
Stieler, J.3
Schwaner, I.4
Heil, G.5
Görner, M.6
Mölle, M.7
Hilbig, A.8
Dörken, B.9
Riess, H.10
Oettle, H.11
-
26
-
-
37549072095
-
-
NCCN, Pancreatic Adenocarcinoma V.1.2009. Available from: URL
-
NCCN. NCCN Clinical Practice Guidelines in Oncology. Pancreatic Adenocarcinoma V.1.2009. Available from: URL: http://www.ccchina.net/UserFiles/2009-4/20/200942001242642.pdf
-
NCCN Clinical Practice Guidelines In Oncology
-
-
-
27
-
-
77749285632
-
Options for the treatment of gemcitabine- resistant advanced pancreatic cancer
-
Gounaris I, Zaki K, Corrie P. Options for the treatment of gemcitabine- resistant advanced pancreatic cancer. JOP 2010; 11: 113-123
-
(2010)
JOP
, vol.11
, pp. 113-123
-
-
Gounaris, I.1
Zaki, K.2
Corrie, P.3
-
28
-
-
55749103379
-
Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer
-
Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 2008; 113: 2046-2052
-
(2008)
Cancer
, vol.113
, pp. 2046-2052
-
-
Xiong, H.Q.1
Varadhachary, G.R.2
Blais, J.C.3
Hess, K.R.4
Abbruzzese, J.L.5
Wolff, R.A.6
-
29
-
-
0023851586
-
Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas
-
Glenn J, Steinberg WM, Kurtzman SH, Steinberg SM, Sindelar WF. Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol 1988; 6: 462-468
-
(1988)
J Clin Oncol
, vol.6
, pp. 462-468
-
-
Glenn, J.1
Steinberg, W.M.2
Kurtzman, S.H.3
Steinberg, S.M.4
Sindelar, W.F.5
-
30
-
-
59149084072
-
CA 19-9 velocity predicts disease-free survival and overall survival after pancreatectomy of curative intent
-
Hernandez JM, Cowgill SM, Al-Saadi S, Collins A, Ross SB, Cooper J, Villadolid D, Zervos E, Rosemurgy A. CA 19-9 velocity predicts disease-free survival and overall survival after pancreatectomy of curative intent. J Gastrointest Surg 2009; 13: 349-353
-
(2009)
J Gastrointest Surg
, vol.13
, pp. 349-353
-
-
Hernandez, J.M.1
Cowgill, S.M.2
Al-Saadi, S.3
Collins, A.4
Ross, S.B.5
Cooper, J.6
Villadolid, D.7
Zervos, E.8
Rosemurgy, A.9
-
31
-
-
58049202340
-
Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: A prospective validation by RTOG 9704
-
Berger AC, Garcia M, Hoffman JP, Regine WF, Abrams RA, Safran H, Konski A, Benson AB, MacDonald J, Willett CG. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol 2008; 26: 5918-5922
-
(2008)
J Clin Oncol
, vol.26
, pp. 5918-5922
-
-
Berger, A.C.1
Garcia, M.2
Hoffman, J.P.3
Regine, W.F.4
Abrams, R.A.5
Safran, H.6
Konski, A.7
Benson, A.B.8
Macdonald, J.9
Willett, C.G.10
-
32
-
-
0032076257
-
Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy
-
Katz A, Hanlon A, Lanciano R, Hoffman J, Coia L. Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy. Int J Radiat Oncol Biol Phys 1998; 41: 393-396
-
(1998)
Int J Radiat Oncol Biol Phys
, vol.41
, pp. 393-396
-
-
Katz, A.1
Hanlon, A.2
Lanciano, R.3
Hoffman, J.4
Coia, L.5
-
33
-
-
61349202170
-
CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy
-
Koom WS, Seong J, Kim YB, Pyun HO, Song SY. CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009; 73: 1148-1154
-
(2009)
Int J Radiat Oncol Biol Phys
, vol.73
, pp. 1148-1154
-
-
Koom, W.S.1
Seong, J.2
Kim, Y.B.3
Pyun, H.O.4
Song, S.Y.5
-
34
-
-
0034009704
-
Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer
-
Halm U, Schumann T, Schiefke I, Witzigmann H, Mössner J, Keim V. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 2000; 82: 1013-1016
-
(2000)
Br J Cancer
, vol.82
, pp. 1013-1016
-
-
Halm, U.1
Schumann, T.2
Schiefke, I.3
Witzigmann, H.4
Mössner, J.5
Keim, V.6
-
35
-
-
27144435114
-
CA19-9 as a prognostic factor in inoperable pancreatic cancer: The implication for clinical trials
-
Maisey NR, Norman AR, Hill A, Massey A, Oates J, Cunningham D. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer 2005; 93: 740-743
-
(2005)
Br J Cancer
, vol.93
, pp. 740-743
-
-
Maisey, N.R.1
Norman, A.R.2
Hill, A.3
Massey, A.4
Oates, J.5
Cunningham, D.6
-
36
-
-
51249103168
-
CA 19-9 response as an early indicator of the effectiveness of gemAltwegg citabine in patients with advanced pancreatic cancer
-
Nakai Y, Kawabe T, Isayama H, Sasaki T, Yagioka H, Yashima Y, Kogure H, Arizumi T, Togawa O, Ito Y, Matsubara S, Hirano K, Sasahira N, Tsujino T, Tada M, Omata M. CA 19-9 response as an early indicator of the effectiveness of gemAltwegg citabine in patients with advanced pancreatic cancer. Oncology 2008; 75: 120-126
-
(2008)
Oncology
, vol.75
, pp. 120-126
-
-
Nakai, Y.1
Kawabe, T.2
Isayama, H.3
Sasaki, T.4
Yagioka, H.5
Yashima, Y.6
Kogure, H.7
Arizumi, T.8
Togawa, O.9
Ito, Y.10
Matsubara, S.11
Hirano, K.12
Sasahira, N.13
Tsujino, T.14
Tada, M.15
Omata, M.16
-
37
-
-
0344837818
-
Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine
-
Saad ED, Machado MC, Wajsbrot D, Abramoff R, Hoff PM, Tabacof J, Katz A, Simon SD, Gansl RC. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer 2002; 32: 35-41
-
(2002)
Int J Gastrointest Cancer
, vol.32
, pp. 35-41
-
-
Saad, E.D.1
Machado, M.C.2
Wajsbrot, D.3
Abramoff, R.4
Hoff, P.M.5
Tabacof, J.6
Katz, A.7
Simon, S.D.8
Gansl, R.C.9
-
38
-
-
41549100207
-
Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer
-
Marechal R, Demois A, Gay F, De Maertelaere V, Arvanitaki M, Hendlisz A, Van Laethema JL. Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer. Oncology 2007; 73: 41-51
-
(2007)
Oncology
, vol.73
, pp. 41-51
-
-
Marechal, R.1
Demois, A.2
Gay, F.3
de Maertelaere, V.4
Arvanitaki, M.5
Hendlisz, A.6
van Laethema, J.L.7
-
39
-
-
77954650702
-
Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer
-
Haas M, Laubender RP, Stieber P, Holdenrieder S, Bruns CJ, Wilkowski R, Mansmann U, Heinemann V, Boeck S. Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer. Tumour Biol 2010; 31: 351-357
-
(2010)
Tumour Biol
, vol.31
, pp. 351-357
-
-
Haas, M.1
Laubender, R.P.2
Stieber, P.3
Holdenrieder, S.4
Bruns, C.J.5
Wilkowski, R.6
Mansmann, U.7
Heinemann, V.8
Boeck, S.9
-
40
-
-
77954771890
-
5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE
-
Fnclcc-ffcd Prodige Group
-
Conroy T, Desseigne F, Ychou M, Ducreux M, Bouche O, Guimbaud R, Fnclcc-ffcd Prodige Group. Randomized phase III trial comparing Folfirinox (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE. J Clin Oncol 2010; 28: 4010
-
(2010)
J Clin Oncol
, vol.28
, pp. 4010
-
-
Conroy, T.1
Desseigne, F.2
Ychou, M.3
Ducreux, M.4
Bouche, O.5
Guimbaud, R.6
|